Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 3/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
| ▸ | PTPRE | P23469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22507908 | 0.94 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL6421816 | 0.87 | MAOB (0.52) | KDM4EALDH1A1HSD17B10HPGDMAOB | |
| SCHEMBL397748 | 0.84 | JAK2 (0.50) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL1305058 | 0.83 | MAOB (0.59) | GAAMAPTMAOBTSHRPTPRC | |
| SCHEMBL4493185 | 0.83 | MAOB (0.49) | KDM4EALDH1A1HSD17B10HPGDMAOB | |
| SCHEMBL15482829 | 0.82 | PTPRC (0.44) | KDM4EALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL6421819 | 0.81 | PTPRC (0.55) | KDM4EALDH1A1HSD17B10HPGDMAOB | |
| SCHEMBL148935 | 0.81 | CHEK1 (0.50) | MAOBABL1PTPRCPTPN2PTPN1 | |
| SCHEMBL21933183 | 0.81 | GPR84 (0.53) | MAOBPTPRCPTPN2PTPN1PTPRB | |
| SCHEMBL31338588 | 0.81 | CHEK1 (0.50) | MAOBABL1PTPRCPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118440063-A | QC and BACE1 multi-targeting inhibitor and preparation method and application thereof | 深圳大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4161651-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| WO-2008147852-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147852-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-04 | — | — | WO | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214529-A9 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | KDM4E 886/4885ALDH1A1 1978/4885GAA 174/4885 |
| US-20080292626-A1 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | KDM4E 886/4885ALDH1A1 1978/4885GAA 174/4885 |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | HCK, BTK, LYN | KDM4E 2333/4885ALDH1A1 4624/4885GAA 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.